Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the ...

The partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to ...

Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue ...

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

Privately-held US genome-scale drug discovery company Orionis Biosciences has announced a second multi-year collaboration ...

Roche (RHHBF) unit Genentech partners Orionis Biosciences to develop and commercialize cancer drugs in a deal that exceed $2B ...

Orionis announced its first collaboration with Genentech, to discover novel small-molecule medicines for challenging targets in major disease areas, including oncology and neurodegeneration ...

The multiyear licensing pact with Orionis Biosciences will use the Boston-based biotech’s Allo-Glue platform to discover and optimize molecular glues for targets designated by Genentech.

Orionis Biosciences has announced a multi-year partnership with Roche’s Genentech, focusing on the discovery and development of small-molecule monovalent glue medicines for difficult targets in ...